William Hrushesky to Fluorouracil
This is a "connection" page, showing publications William Hrushesky has written about Fluorouracil.
Connection Strength
0.927
-
Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther. 2006 Aug; 5(8):2023-33.
Score: 0.254
-
Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2000 Mar 01; 46(4):873-81.
Score: 0.163
-
Fertility maintenance and 5-fluorouracil timing within the mammalian fertility cycle. Reprod Toxicol. 1999 Sep-Oct; 13(5):413-20.
Score: 0.157
-
More evidence for circadian rhythm effects in cancer chemotherapy: the fluoropyrimidine story. Cancer Cells. 1990 Mar; 2(3):65-8.
Score: 0.081
-
Circadian organization of thymidylate synthase activity in normal tissues: a possible basis for 5-fluorouracil chronotherapeutic advantage. Int J Cancer. 2000 Nov 01; 88(3):479-85.
Score: 0.043
-
Unusual pigmentary changes associated with 5-fluorouracil therapy. Cutis. 1980 Aug; 26(2):181-82.
Score: 0.042
-
Letter: Serpentine supravenous fluorouracil hyperpigmentation. JAMA. 1976 Jul 12; 236(2):138.
Score: 0.032
-
Serpentine supravenous 5-fluorouracil (NSC-19893) hyperpigmentation. Cancer Treat Rep. 1976 May; 60(5):639.
Score: 0.031
-
Cancer chronotherapy: is there a right time in the day to treat? J Infus Chemother. 1995; 5(1):38-43.
Score: 0.028
-
Circadian pharmacodynamics of anticancer therapies. Clin Chem. 1993 Nov; 39(11 Pt 2):2413-8.
Score: 0.026
-
Cancer chronotherapy: a drug delivery challenge. Prog Clin Biol Res. 1990; 341A:1-10.
Score: 0.020
-
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. Clin Colorectal Cancer. 2008 Mar; 7(2):134-9.
Score: 0.018
-
High-dose intensity systemic therapy of metastatic bladder cancer. J Clin Oncol. 1987 Mar; 5(3):450-5.
Score: 0.017
-
Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol. 2005 Sep; 16(9):1449-57.
Score: 0.015